Sinovent Completes 1 Billion RMB Series C Financing, Jointly Led by Loyal Valley Capital and Internationally Renowned Long-term Funds

0
165

In August 2020, Suzhou Sinovent Pharmaceutical Technology Co., Ltd. (“Sinovent”) successfully completed a Series C round of financing of RMB 1 billion. This round of financing was jointly led by Loyal Valley Capital and internationally renowned long-term funds. Oceanpine Capital, CICC Qide Fund, SilliconX.AI, Jiuyo Capital, Deguan Capital and other well-known institutions participated in the joint venture. StartPoint Advisors served as the exclusive financial advisor for this round of financing.

Founded in 2016, Sinovent is an innovative drug company focusing on major unmet clinical needs and possessing global intellectual property rights. Relying on its Suzhou headquarters, Sinovent has established four branches in Beijing, Shanghai, Australia, and Boston, and built a complete global R&D and production system. The team includes the industry’s top scientific research, clinical, production and sales talents. Won important awards such as Suzhou Unicorn Cultivation Enterprise, Jiangsu Double Innovation Project, and Gusu Leading Talent.

The company has carried out a series of layouts around the two strategic dimensions of the mature target next-generation “Best in class” product and the new target “First in class” product. At present, 4 products have entered the clinical stage at home and abroad, and 4 products are in the IND enabling stage, covering major fields such as tumor, anti-infection, metabolism, autoimmunity, etc. Funds raised in this round will be mainly used to promote the company’s ongoing domestic and foreign clinical trials, preclinical research and development of early projects, and construction of production bases, and promote the early listing of products to benefit the majority of patients.

Among the product pipelines that have entered the clinical, XNW4107 is a new type of β-lactamase inhibitor that has strong killing ability against Gram-negative bacteria, and at the same time, against Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae Bacteria. The antibacterial effect is better than similar products on the market or in the clinical stage. XNW3009 is a new generation of uric acid lowering drugs. The current clinical data shows good safety and excellent efficacy. XNW1011 is the second BTK inhibitor with a covalent reversible mechanism in the world. It is expected to surpass the previous generation of products in terms of safety, efficacy and indications. XNW7201 is a small molecule inhibitor of the Wnt pathway. It is expected to show significant efficacy in the treatment of gastrointestinal tumors such as gastric cancer, colorectal cancer, and pancreatic cancer. It can also enhance immune response and is suitable for combined use with tumor immunosuppressants.

The founder and chairman of the company, Mr. Qiang Jing, expressed his gratitude to the well-known institutional investors and the Suzhou Park Government for their support. Sinovent has established a complete team system, covering biology, medicinal chemistry, CMC, translational medicine, clinical pharmacology, clinical, sales, capital market and other component, and each component is equipped with industry-leading professionals . In the layout of the product line, it also fully considered unmet clinical needs and differentiated advantages over other similar products, taking into account the success rate of research and development and the commercial value of the product. In the future, Sinovent will keep its promises, maintain its original intention, and continue to focus. In major areas such as oncology and anti-infection, we will continue to enrich the product line and strive to provide patients with more good medicines.

As the leading investor of this round, Mr. Lin Lijun, founder of Loyal Valley Capital said, “We are very honored to continue to support Sinovent this round. Loyal Valley Capital focuses on investing in great companies, using investment to make the world a better place, and is committed to supporting entrepreneurs who pursue excellence, and through long-term and continuous efforts, to build world-class excellent companies. Sinovent is an innovative drug research and development company with strong independent research and development capabilities and systematic operation capabilities. The company is committed to developing a new generation of small molecule drugs for patients around the world to solve urgent unmet clinical needs such as anti-infection and tumors. I am very optimistic that the company’s XNW4107 and its follow-up products will continue to bring value to patients and society. It is in line with Loyal Valley Capital’s investment philosophy of “long-term, focused, and altruistic”. Loyal Valley Capital will also firmly support Sinovent’s R&D and Production, industrialization, and sales, supporting Sinovent to become the world’s leading innovative drug research and development company.

Fu Jia, the managing director of StartPoint Advisors said, “Sinovent is a rare domestic new drug leader with deep product innovation and super execution. Its unique pipeline positioning is unique among domestic innovative drug companies. Since its establishment, Sinovent has been highly recognized by the government, industry and capital along the way. In Suzhou, where the company’s headquarters is located, Sinovent has won awards for many years. The StartPoint Advisors team is honored to be able to provide financial advisory services to a star company such as Sinovent, and sincerely wish that Sinovent will successfully land in the capital market in the near future and grow into a Big Pharma in China and even the world!

>>>>
About Sinovent:

Suzhou Sinovent Pharmaceutical Technology Co., Ltd. was established in 2016. It is an innovative drug company that focuses on major unmet clinical needs and has global intellectual property rights. Sinovent has carried out a series of layouts around the two strategic dimensions of the mature target “Best in class” product and the new target “First in class” product. At present, 4 products have entered the clinical stage at home and abroad, and 4 products are in the IND enabling stage, covering major fields such as tumor, anti-infection, metabolism, autoimmunity, etc.

LEAVE A REPLY

Please enter your comment!
Please enter your name here